About Us

As a global total healthcare company,
we aim to become The Health Innovator.
About Handok
Handok is pioneering new fields, collaborating with world-class enterprises, and leading the healthcare industry in South Korea. Since its founding in 1954, Handok has established global standard systems and introduced advanced pharmaceutical technologies and superior medicines to South Korea through partnerships with leading global pharmaceutical companies. In 2012, after 49 years of joint ventures, Handok became an independent company and declared its vision to become The Health Innovator as a global total healthcare company, expanding its business domains beyond treatment to include diagnosis and management.
  • Established 1954 * July 1
  • Listed 1976 * June 30
  • Employees 985 * as of December 2023
  • Revenue 518 * KRW billion, 2023
 
  • Handok Inc.
  • 132 Teheran-ro, Gangnam-gu, Seoul
  • Young-Jin Kim, Chairman & CEO / Jin-Ki Baek, Vice President
  • +82-2-527-5114
  • Manufacturing of finished pharmaceutical products
  • December
 
Company Introduction Video

Imagination is something anyone can have, but turning imagination into reality requires a special kind of power. Handok finds that answer in innovation. With a long-standing DNA of innovation, Handok ventures into uncharted territories, turning ideas for a healthier world into reality.

The Health Innovator, Handok

 
Main Business Areas
 
Subsidiaries and Affiliates
  • Subsidiary THERAVAULES

    Based in Tokyo, THERAVALUES develops functional ingredients like Theracurmin with enhanced bioavailability.

  • Subsidiary INNOCUVE

    INNOCUVE is a bio healthcare accelerator that fosters startups with a unique business model tailored to the domestic bio healthcare industry.

  • Affiliate TEVA-HANDOK

    TEVA-HANDOK is a joint venture established by Handok and the global Top 10 pharmaceutical company Teva, developing and supplying innovative new drugs and generics.

  • Affiliate Genexine

    Genexine is a first-generation biotech company in South Korea, developing biopharmaceuticals for incurable diseases based on next-generation sustained platform technology, hyFcTM, and DNA vaccine technology.

  • Affiliate NB POSTECH

    Founded in 2008 as the first technology holding company of POSTECH, NB POSTECH specializes in developing biochips.

  • Affiliate REZOLUTE

    Established in 2010, Resolute is a biopharmaceutical development company focusing on innovative treatments for metabolic rare diseases.

  • Affiliate Sobi-Handok

    Sobi-Handok is a joint venture established by Handok and Sobi with a common investment for the rare disease business. Sobi is a Swedish biopharmaceutical company that is experiencing rapid growth with its innovative treatments for rare diseases

News
맨위로